

Supplementary Table 3. Post infusional effect of the CAR-T on the biomarkers' levels depending on the administered construct.

Biomarker	Baseline	24h-INF	P value* (24h-INF – Baseline)
Varnimcabtagene autoleucel n= 29			
sVCAM-1 (ng/mL)	539±636	711±1412	0.184
sTNFRI (pg/mL)	1738±1097	2449±2360	0.079
TM (ng/mL)	3393±1972	3493±1403	0.184
ST2 (ng/mL)	25± 27	206±261	0.170
Ang-2 (pg/mL)	1370 ± 924	2826±4326	<0.001*
NETs (µg/mL)	7±7	10±7	0.017*
sC5b-9 (ng/mL)	654±391	902±1781	0.222
VWF:Ag (%)	157±193	166±152	0.08
A13 (%)	90±29	73±16	0.046*
α-2 AP (%)	101±43	89±17	0.150
PAI-1 Ag (ng/mL)	31±41	54±34	0.779
ARI0002h n= 16			
sVCAM-1 (ng/mL)	30±32	56±32	0.496
sTNFRI (pg/mL)	3096±2053	3871±1065	0.826
TM (ng/mL)	4217±1221	2830±1705	0.363
ST2 (ng/mL)	37±44	22±25	0.300
Ang-2 (pg/mL)	1182±1023	1998±1009	0.300
NETs (µg/mL)	5±2	5±1	0.550
sC5b-9 (ng/mL)	589±929	684±1041	0.272
VWF:Ag (%)	116±113	103±1066	0.910
A13 (%)	90±19	82±35	0.465
α-2 AP (%)	113±23	114±18	0.198
PAI-1 Ag (ng/mL)	26±36	36±34	0.754
Axicabtagene Ciloleucel n= 14			
sVCAM-1 (ng/mL)	208±323	181±229	0.433
sTNFRI (pg/mL)	3055±4691	2840±3257	0.158
TM (ng/mL)	4172±3543	3225±3152	0.300
ST2 (ng/mL)	54±84	50±74	0.140
Ang-2 (pg/mL)	1798±2447	1647±2662	0.56
NETs (µg/mL)	8±7	7±9	0.095
sC5b-9 (ng/mL)	476±581	472±557	0.510
VWF:Ag (%)	198±202	171±194	0.683
A13 (%)	89±39	76±18	0.678
α-2 AP (%)	100±43	97±46	0.397
PAI-1 Ag (ng/mL)	29±17	36±23	0.177
Lisocabtagene maraleucel n=3			
sVCAM-1 (ng/mL)	242±308	326±472	1
sTNFRI (pg/mL)	2293±490	3081±864	0.109
TM (ng/mL)	3609±1053	3370±473	0.593
ST2 (ng/mL)	25±6	74±100	1
Ang-2 (pg/mL)	1225±620	1294±591	0.593

NETs ($\mu\text{g/mL}$)	9 \pm 2	8 \pm 2	0.414
sC5b-9 (ng/mL)	600 \pm 288	460 \pm 193	0.109
VWF:Ag (%)	151 \pm 96	144 \pm 72	0.593
A13 (%)	90 \pm n.a	78 \pm n.a	n.a
α -2 AP (%)	111 \pm 25	100 \pm 22	0.109
PAI-1 Ag (ng/mL)	39 \pm 15	53 \pm 23	0.285

***Wilcoxon test.**

Values are expressed as median \pm interquartile range (IQR) or percentage (as indicated); sVCAM-1: soluble vascular cell adhesion molecule 1; 24h-INF: sample collected 24-48h after CAR-T cell infusion, sTNFRI: soluble TNF receptor 1; TM: Thrombomodulin; sST2: soluble suppression of tumorigenesis-2; ANG-2: Angiopoietin-2; NETs: Neutrophil Extracellular Traps or Circulating dsDNA; sC5b9= soluble C5b9; VWF:Ag: von Willebrand factor antigen; A13: ADAMTS-13 activity; α -2 AP: alpha-2-antiplasmin; PAI-1 Ag: Inhibitor of the activator of plasminogen antigen. *P was considered statistically significant when <0.05 . IQR was not calculated in Lisocabtagene maraleucel cases due to the limited n. In this case, mean and standard deviation (mean \pm SD) is shown. SD of A13 could not be calculated since the determination was made only in one patient in this group.